News

  • 8 May 2019

    AstraZeneca’s Calquence Ascend trial meets primary endpoint

    British-Swedish pharmaceutical and biopharmaceutical company AstraZeneca has announced that the Phase III Ascend trial of Calquence (acalabrutinib) in previously-treated patients with chronic lymphocytic leukaemia (CLL) has met the primary endpoint.

Go Top